Tibsovo Market Forecasted to Reach USD $1.7 Billion by 2030 at 9.3% CAGR

The Business Research Company’s 2026 market reports introduce new features such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, all designed to enhance the depth, usability, and strategic value of the insights provided.

What Is the Growth Potential of the Ticagrelor Market in the Next Decade?
The tibsovo market size has grown strongly in recent years. It will grow from $1.08 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to limited availability of idh1-targeted drugs, growing prevalence of aml and cholangiocarcinoma, reliance on conventional chemotherapy, low awareness of genetic mutation testing, restricted access to specialized oncology clinics.

The tibsovo market size is expected to see strong growth in the next few years. It will grow to $1.7 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to development of novel oral targeted therapies, increasing genetic testing and personalized medicine adoption, expansion of combination treatment regimens, rising investment in oncology research, growth of hospital and specialty clinic networks. Major trends in the forecast period include rising adoption of targeted therapies for aml and cholangiocarcinoma, increasing use of oral targeted drugs over intravenous administration, expansion of combination therapy approaches, growing awareness of idh1 mutation testing, enhanced focus on personalized cancer treatment.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/report/tibsovo-global-market-report

Which Major Growth Factors Are Shaping the Tibsovo Market?
The increasing prevalence of acute myeloid leukemia is expected to propel the growth of the tibosovo market going forward. Acute myeloid leukemia (AML) refers to an aggressively progressing cancer of the blood and bone marrow that directly impacts blood cell production, immune function, and overall physical health. The prevalence of acute myeloid leukemia is increasing largely due to the global rise in the aging population, as the disease primarily affects older adults, and longer life expectancy means more individuals are reaching the age group most susceptible to developing this form of leukemia. Tibsovo helps acute myeloid leukemia by targeting IDH1-mutated cancer cells to inhibit abnormal cell growth, reduce disease progression, enhance treatment response, and improve survival outcomes by restoring normal blood cell production. For instance, in February 2023, according to the report published by the Leukemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults (25–65) are expected to be diagnosed with blood cancers, mainly including ALL, AML, and non-Hodgkin lymphoma. Therefore, the increasing prevalence of acute myeloid leukemia is driving the growth of the tibsovo market.

What Are the Key Segments in the Tibsovo Market?
The tibsovo market covered in this report is segmented –

1) By Product: Tablets, Combination Therapy
2) By Drug Administration: Oral Administration, Intravenous Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Cancer Treatment, Acute Myeloid Leukemia, Targeted Therapy
5) By End User: Hospitals, Specialty Clinics, Research Institutions, Homecare Settings

Subsegments:
1) By Tablets: Oral Tablets, Extended-Release Tablets
2) By Combination Therapy: Tibsovo + Chemotherapy Agents, Tibsovo + Targeted Therapy Agents

Which Trends Are Most Likely to Influence Tibsovo Market Growth in the Next Decade?
Major companies operating in the tibsovo market are focusing on obtaining regulatory approvals to broaden the drug’s reach and maintain its leadership in IDH1-mutated cancers. Regulatory approvals refer to official permissions granted by health authorities that allow a drug to be legally marketed and used for specific medical conditions after confirming its safety and effectiveness. For instance, in October 2023, Servier Laboratoires, a France-based pharmaceutical company, received approval from the European Commission for tibsovo (ivosidenib tablets), marking it as the first and only IDH1-targeted therapy authorized in Europe for two challenging cancer types. It is approved for use in combination with azacitidine for newly diagnosed acute myeloid leukemia (AML) patients with an IDH1 R132 mutation who are ineligible for standard induction chemotherapy and as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma harboring the same mutation after at least one prior systemic treatment. This approval, which benefits from orphan drug designation, addresses critical unmet medical needs and provides new hope for better outcomes and quality of life for these patients.

Which Major Companies Are Operating in the Tibsovo Market?
Major companies operating in the tibsovo market are Servier Laboratoires, Agios Pharmaceuticals

Get the full tibsovo market report here:
https://www.thebusinessresearchcompany.com/report/tibsovo-global-market-report

How Does Tibsovo Market Growth Vary Across Major Regions?
North America was the largest region in the tibsovo market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tibsovo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: Global Market Research Reports & Consulting | The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn